Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Pinkal M DesaiJanice BrownSaar I GillMelham M SolhLuke P AkardJack W HsuCelalettin UstunCharalambos AndreadisOlga FrankfurtJames M ForanJohn ListerGary J SchillerMatthew J WieduwiltJohn M PagelPatrick Joseph StiffDelong LiuIrum KhanWendy StockSuman KambhampatiMartin S TallmanLawrence MorrisJohn EdwardsIskra PusicHagop M KantarjianRichard MamelokAlicia WongRodney Van SyocLois KellermanSwapna PanugantiRamkumar MandalamCamille N AbboudFarhad RavandiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Subjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy.
Keyphrases